Latest Breaking News On - Alnylam pharmaceuticals daily - Page 6 : comparemela.com

Motley Fool Asset Management LLC reduced its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 8.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,035 shares of the biopharmaceutical company’s stock after selling 196 shares during the period. Motley […]

Motley fool asset managementNews ratings for alnylam pharmaceuticals dailyWells fargo companyRaymond james associatesS capital wealth advisorsJpmorgan chase coAlnylam pharmaceuticals stock performanceQuarter for alnylam pharmaceuticalsExchange commissionAlnylam pharmaceuticals incHarbor capital advisors incCommonwealth equity servicesAlnylam pharmaceuticals profileAlnylam pharmaceuticalsWolfe researchXponance inc